Showing results (141-150 of 247) with videos related to

Sort By:
Pageof 25
British Journal of Clinical Pharmacology|September 1, 1996
Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissueK T Kivistö, G Bookjans, M F Fromm, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 4, 2001
P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxinC Pauli-Magnus, T Mürdter, A Godel, et al.
Clinical Pharmacology and Therapeutics|May 29, 2009
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatinJ E Keskitalo, O Zolk, M F Fromm, et al.
British Journal of Clinical Pharmacology|August 1, 1990
A mechanism of D-(+)-sotalol effects on heart rate not related to beta-adrenoceptor antagonismC Funck-Brentano, D J Silberstein, D M Roden, et al.
The American Journal of Cardiology|September 1, 1984
Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dogA K Dawson, D M Roden, H J Duff, et al.
Circulation|October 15, 1996
Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTSD M Roden, R Lazzara, M Rosen, et al.
Clinical Pharmacology and Therapeutics|June 1, 1988
Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointesK A Thompson, J J Murray, I A Blair, et al.
The American Journal of Cardiology|March 1, 1988
Tocainide plus quinidine for treatment of ventricular arrhythmiasJ T Barbey, K A Thompson, D S Echt, et al.
Circulation Research|May 1, 1988
Quinidine delays IK activation in guinea pig ventricular myocytesD M Roden, P B Bennett, D J Snyders, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1988
Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibersK A Thompson, D H Iansmith, L A Siddoway, et al.
Pageof 25